Frequency of NRAS Gene Mutation in Wild Type KRAS and BRAF Colorectal Cancers; a Single Center Study

Hooria Momenzadeh1, Mitra Mirzai1, Zahra Jowkar1, Bita Geramizadeh1,2,*

ABSTRACT

BACKGROUND

Incidence of colorectal cancer is increasing in countries such as Iran. Molecular biomarkers play very important role in the diagnosis, treatment, and prognosis of this cancer. Mutation in the RAS family (including KRAS and NRAS) is one of these important molecular biomarkers, which should be tested before starting treatment with anti-EGRF (Epidermal growth factor) drugs.

Objectives: There has been very few reports about the frequency of NRAS mutation from Iran and no study from south of the country. In this article we will describe our experience about the frequency of NRAS mutation in colorectal cancers from the largest referral center in the south of Iran.

METHODS

During 5 years (2011-2015), we had 52 cases of colorectal cancers with wild type KRAS and BRAF in the hospitals affiliated to Shiraz University of Medical Sciences with enough tissue for molecular studies. NRAS mutation analysis was performed on paraffin embedded formalin fixed tissue of these cases by polymerase chain reaction (PCR)-sequencing method.

RESULTS

Among these 52 cases of colorectal cancer with wild type KRAS and BRAF, there has been 3 (5.7%) cases with mutant NRAS. One of the mutations has been in codon 12 and two in codon 61. No mutation in codon 13 was found. All the three cases were women with stage IV and well differentiated histomorphology.

CONCLUSION

Our results showed that frequency of NRAS mutation in colorectal cancer is rare, which is very close to other studies from different geographic areas of the world.

KEYWORDS:
Gene mutation, Colorectal cancers, Molecular biomarkers

Please cite this paper as:

INTRODUCTION

Colorectal cancer is the fourth common cancer in men and the third common in women.1,2 In eastern countries such as Iran, its incidence has significantly increased during the last few years.3 Tumor genotyping is rapidly being integrated into routine clinical care to define the most appropriate targeted therapy.3,4 One of the most important molecular biomarkers of the human cancers (including colorectal adenocarcinoma) are the RAS family members (KRAS, NRAS, and HRAS), which are frequently found in their mutated, oncogenic forms in hu-
man tumors. Activating mutations in the RAS genes occur in approximately 20% of all human cancers, mainly in codons 12, 13, or 61. Among the RAS family, mutations in KRAS account for about 85% of all RAS mutations in human tumors; NRAS for about 15%; and HRAS for less than 1%. RAS mutations are useful markers for predicting responses to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (like cetuximab or panitumumab), especially in metastatic colorectal cancers (CRC). Approximately 30-50% of CRCs have KRAS mutations and currently, the KRAS status is known to be a selective marker of predicting response to anti-EGFR antibodies. The tumors of patients with metastatic CRC are now investigated routinely for KRAS mutations before receiving cetuximab or panitumumab. However, previous studies have shown that, in more than half (up to 65%) of the patients with wild type KRAS gene, CRC still fails to respond to anti-EGFR therapy. This suggests the involvement of mutations at other locations of gene or other genes that act downstream of EGFR in the RAS/RAF/MEK/ERK pathway. Regarding this point, it is recommended to test for KRAS mutation as the first step and then in wild type KRAS, analysis for BRAF mutation should be the second step. In the presence of wild type BRAF, NRAS mutation analysis should be the third step, and PIK3CA exon 20 should be analysed as the fourth and final step. KRAS and BRAF are mutually exclusive. Many studies have shown that the NRAS mutation affects the efficacy of anti-EGFR antibodies and is significantly associated with a low response rate to these drugs. Also some studies have shown significant association of NRAS mutation with specific locations of colon involvements and distant metastasis in CRC.

To the best of our knowledge only two published studies have been reported from Iran about the frequency of NRAS in KRAS and BRAF mutation negative CRCs. In this study, we want to identify NRAS mutations and spectrum (at codons 12, 13, and 61) in 52 KRAS and BRAF wild type during 5 years (2011-2015) in the hospitals affiliated to Shiraz University of Medical Sciences as the largest referral center in south of Iran.

**MATERIALS AND METHODS**

During 5 years from June 2011 to June 2015, all wild type KRAS and BRAF CRCs who were referred to hospitals affiliated to Shiraz University of Medical Sciences and had enough tissue for molecular studies, were included in this study. Recurrent and post chemotherapy cases were excluded from the study. It means that none of our cases had been treated. In the meanwhile all of them were sporadic cases of CRC with no case of Lynch Syndrome. Hematoxylin and Eosin slides were reviewed and proper slides with minimum necrosis and maximum well preserved tumor cells (at least 50% of tumor cells) were selected. NRAS codon 12, 13, and 61 mutations were investigated by using polymerase chain reaction (PCR) and direct sequencing (Sanger). DNA extraction and purification of each case was performed from paraf-
fin embedded formalin fixed (PEFF) tissue using Qiagen extraction and purification kit. Then PCR amplification of DNA was done (figures 1 and 2) followed by DNA sequencing by Sanger method (figure 3).

RESULTS

During these 5 years we collected 52 cases of CRCs with wild type KRAS and BRAF, which were included in this study. Age range of the patients was 26 to 85, with mean age of 57.92 ± 13.93 years. There were 29 male and 23 female patients in this study population. Among these cases 15 CRCs were in sigmoid colon, 14 in ascending colon, 13 in rectum, 5 in descending colon, 4 in rectosigmoid, and 1 in transverse colon. Most of the cases were well differentiated (69%), T3 (50%), and polypoid (40%).

Among these 52 KRAS and BRAF wild type patients with CRC, there were 3 (5.7%) patients with mutations in NRAS gene. The remaining 49 patients showed wild type NRAS.

Of the three mutant individuals, one of the mutations was located in codon 12, leading to the substitution of Guanine by Thymidine (35G > T) (normal sequence of the codon 12 = GGT, replaced by GTT), resulting in amino acid substitution of glycine to valine.

In both of the other two mutant individuals, the mutations were detected in codon 61, one of which led to the substitution of cytosine by adenine (181C > A) (normal sequence of the codon 61 = CAA, replaced by AAA), resulting in amino acid substitution of glutamine to lysine. The second one resulted the substitution of adenine by thymidine (182A > T) (normal sequence of the codon 61 = CAA, replaced by CTA), resulting in amino acid substitution of glutamine to leucine. No mutation in codon 13 was detected.

All the three mutant patients were women with age ≥ 40 years (mean: 50.33). All the three cases were stage IV, and well differentiated. Two of the mutant cases were located in sigmoid colon, and the other one in rectum.

DISCUSSION

CRC is one of the common cancers in human beings with growing incidence in eastern countries such as Iran. There are important molecular features in this cancer such as mutations in RAS family (KRAS, NRAS, and HRAS). Among the RAS family, mutations in KRAS accounts for about 85% of all RAS mutations in human tumors, NRAS for about 15%, and HRAS for less than 1%. NRAS is identical to KRAS in the first 85 amino acids. However, unlike KRAS, NRAS is not activated by specific cytokines or growth factors, so mutant NRAS protects CRC cells from stress-induced apoptosis. These mutations of NRAS mostly occur in codons 12 and 13 (exon 2), 61 (exon 3), 117, and 146 (exon 4). There is a low chance for cancer cells with mutated forms of KRAS and NRAS genes to respond to treatment by anti-EFGER (epidermal growth factor) monoclonal antibodies, and cancer and metastasis may continue to progress in spite of treatment. Examples of such drugs are cetuximab and panitumumab.

There are reports about worse prognosis of CRCs with NRAS mutations. Early identification of mutations should be performed to guide patients with metastatic CRC toward targeted therapies. Many studies have proved the impact of NRAS genes activating mutations, on prognosis and resistance (low response) to anti-EGFR therapy. In CRCs with wild type KRAS gene, analysis of NRAS mutations is considered necessary.

As indicated by the result of our study, among 52 KRAS and BRAF wild type patients with CRC, there were 3 (5.7%) patients with mutations in NRAS gene. No NRAS mutation was detected in the remaining 49 patients (wild type NRAS gene).

In concordance with our results, in previous studies, NRAS mutations have been also rarely detected. The overall frequency of NRAS mutations in CRC has ranged between 2-7. 4% (table 1 and 2). As shown in the table, the difference in frequencies is secondary to
ethnic variations. Some studies have reported the incidence of NRAS in wild type KRAS and BRAF, while some others searched NRAS mutation frequency in both mutant and wild type KRAS and BRAF CRCs. In wild type KRAS and BRAF, NRAS mutation rate has been reported to be between 2.4% to 4.7%.29-36 Only two studies from Iran previously showed NRAS mutation frequencies of 0 and 2% (table 2).17,18 Our results are very close to the reports from the other parts of the world but we report a little higher mutation rate in wild type KRAS

Table 1: Reported frequencies of NRAS mutations in different countries of Asia, America, and Europe

<table>
<thead>
<tr>
<th>Author</th>
<th>Country</th>
<th>Year</th>
<th>Method</th>
<th>Sample size</th>
<th>KRAS and BRAF</th>
<th>NRAS mutation</th>
<th>Most common Mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Al Shamsi HO</td>
<td>USA (Arab Population)</td>
<td>2016</td>
<td>PCR-NGS*</td>
<td>99</td>
<td>Wild</td>
<td>4%</td>
<td>NR**</td>
</tr>
<tr>
<td>Chang Y- Yao</td>
<td>Taiwan</td>
<td>2016</td>
<td>PCR-Sequencing</td>
<td>1519</td>
<td>Wild and mutant</td>
<td>4.3%</td>
<td>61</td>
</tr>
<tr>
<td>Shen Y</td>
<td>China</td>
<td>2013</td>
<td>PCR-Sequencing</td>
<td>621</td>
<td>Wild and mutant</td>
<td>4.19%</td>
<td>61</td>
</tr>
<tr>
<td>Zhang J</td>
<td>China</td>
<td>2015</td>
<td>PCR-Sequencing</td>
<td>1110</td>
<td>Wild and mutant</td>
<td>3.9%</td>
<td>12</td>
</tr>
<tr>
<td>Bando H</td>
<td>Japan</td>
<td>2013</td>
<td>PCR-Sequencing</td>
<td>82</td>
<td>Wild</td>
<td>2.4%</td>
<td>12</td>
</tr>
<tr>
<td>Soeda H</td>
<td>Japan</td>
<td>2014</td>
<td>PCR-Sequencing</td>
<td>43</td>
<td>Wild</td>
<td>4.7%</td>
<td>12</td>
</tr>
<tr>
<td>Bagadie SP</td>
<td>India</td>
<td>2012</td>
<td>PCR-Sequencing</td>
<td>100</td>
<td>NR</td>
<td>2%</td>
<td>NR</td>
</tr>
<tr>
<td>Palomba G</td>
<td>Italy</td>
<td>2016</td>
<td>PCR-Sequencing</td>
<td>1288</td>
<td>Wild</td>
<td>4.1%</td>
<td>NR</td>
</tr>
<tr>
<td>Modest DP</td>
<td>Germany</td>
<td>2016</td>
<td>PCR-Sequencing</td>
<td>1239</td>
<td>NR</td>
<td>3.1%</td>
<td>NR</td>
</tr>
<tr>
<td>Bulschun K</td>
<td>Germany</td>
<td>2011</td>
<td>PCR-Sequencing</td>
<td>57</td>
<td>KRAS: Mutant and wild</td>
<td>3.5%</td>
<td>61</td>
</tr>
<tr>
<td>Scalfani F</td>
<td>Europe</td>
<td>2014</td>
<td>PCR-Sequencing</td>
<td>90</td>
<td>Wild type</td>
<td>4.4%</td>
<td>3</td>
</tr>
<tr>
<td>Douillard NY</td>
<td>Europe</td>
<td>2013</td>
<td>PCR-Sequencing</td>
<td>641</td>
<td>KRAS: Mutant and wild</td>
<td>7.4%</td>
<td>61</td>
</tr>
<tr>
<td>Peeters M</td>
<td>USA, Europe</td>
<td>2013</td>
<td>PCR-NGS</td>
<td>282</td>
<td>Kras: Mutant and wild</td>
<td>5%</td>
<td>NR</td>
</tr>
<tr>
<td>Morris VK</td>
<td>USA</td>
<td>2014</td>
<td>PCR-Sequencing</td>
<td>484</td>
<td>NR</td>
<td>4.1%</td>
<td>61</td>
</tr>
<tr>
<td>Vaughn CP</td>
<td>USA</td>
<td>2011</td>
<td>PCR-Sequencing</td>
<td>513</td>
<td>Kras: Mutant and wild</td>
<td>5.06%</td>
<td>61</td>
</tr>
<tr>
<td>Irahara N</td>
<td>USA</td>
<td>2010</td>
<td>PCR</td>
<td>225</td>
<td>Wild</td>
<td>2.2%</td>
<td>12</td>
</tr>
<tr>
<td>Russo A</td>
<td>USA</td>
<td>2014</td>
<td>SNAPshot Multiplex system</td>
<td>222</td>
<td>Wild</td>
<td>4.05%</td>
<td>12</td>
</tr>
<tr>
<td>De Rook</td>
<td>Europe</td>
<td>2010</td>
<td>PCR</td>
<td>644</td>
<td>Wild</td>
<td>2.6%</td>
<td>61</td>
</tr>
</tbody>
</table>

(NR: Not reported; NGS: nest generation sequencing)

Table 2: Reported studies about NRAS mutations from Iran

<table>
<thead>
<tr>
<th>Author</th>
<th>Country</th>
<th>Year</th>
<th>Method</th>
<th>Sample size</th>
<th>KRAS and BRAF</th>
<th>NRAS mutation</th>
<th>Most common mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naseri et al.</td>
<td>Iran</td>
<td>2016</td>
<td>Real time-sequencing</td>
<td>50</td>
<td>Not Reported</td>
<td>2%</td>
<td>Codon 146 (exon3): (436G &gt; A) Ala to Thr</td>
</tr>
<tr>
<td>Payande et al.</td>
<td>Iran</td>
<td>2016</td>
<td>Allele specific-sequencing</td>
<td>83</td>
<td>Not Reported</td>
<td>4.3%</td>
<td>Not reportd</td>
</tr>
<tr>
<td>Current Study</td>
<td>Iran</td>
<td>2016</td>
<td>PCR-Sequencing</td>
<td>50</td>
<td>Wild type</td>
<td>5.7%</td>
<td>Codon 61 181C &gt; A and 182A &gt; T</td>
</tr>
</tbody>
</table>
and BRAF CRCs compared with the previous reports i.e. 5.7% versus 2.2% to 4.7%. This difference could probably be due to differences in geographic region as well as ethnic population.13,15,27,30,32-34

Our study showed no statistically significant associations, between NRAS mutations and clinicopathological features such as age, sex, tumor site, stage, and tumor histological grade. Most of the previous studies have also reported the same results with no significant difference between factors such as age, sex, tumor location, stage of disease, and tumor grade with NRAS mutations (p > 0.05).27,29

CONCLUSION

Iranian patients with CRC can benefit from routine mutational status analysis, before starting the treatment with anti-EGFR antibody drugs. Therefore NRAS mutation although is rare, should be definitely investigated in wild type KRAS and BRAF, before treatment, because according to our findings, about 5.7% of the patients with CRCs and wild type KRAS and BRAF, would have NRAS mutation, which causes negative interference with anti-EGFR treatment.

ACKNOWLEDGEMENTS

This thesis has been performed by the financial support of Shiraz University of Medical Sciences (project No-8489)

ETHICAL APPROVAL

There is nothing to be declared.

CONFLICT OF INTEREST

The authors declare no conflict of interest related to this work.

REFERENCES


